First‐trimester screening for Down syndrome in France combining fetal nuchal translucency measurement and biochemical markers

@article{Muller2003FirsttrimesterSF,
  title={First‐trimester screening for Down syndrome in France combining fetal nuchal translucency measurement and biochemical markers},
  author={Françoise Muller and Clarisse Benattar and François Audibert and Nathalie Roussel and Sophie Dreux and Howard Cuckle},
  journal={Prenatal Diagnosis},
  year={2003},
  volume={23}
}
In France, there is a strictly regulated National Screening Programme for Down syndrome, based on second‐trimester maternal serum markers. A prospective study of nuchal translucency together with retrospective evaluation of maternal serum markers was carried out to inform decisions on whether to move the programme to the first trimester. 
First‐trimester combined ultrasound and biochemical screening for Down syndrome in routine clinical practice
TLDR
To assess the effectiveness of combined ultrasound and biochemical screening for chromosome abnormalities in singleton pregnancies in a routine antenatal clinic and laboratory setting, a large number of patients were referred to a single clinic or laboratory for screening.
First‐trimester Down syndrome screening performance in the Dutch population; how to achieve further improvement?
To study the performance of the first‐trimester combined test between 2004 and 2006 compared to a previous period to investigate changes in time and identify reasons for sub‐optimal performance.
Follow up and evaluation of the Victorian first‐trimester combined screening programme for Down syndrome and trisomy 18
TLDR
This study followed up and evaluated the statewide first‐trimester combined screening programme for Down syndrome and trisomy 18 at Genetic Health Services Victoria, Australia.
Second‐trimester Down syndrome maternal serum marker screening: a prospective study of 11 040 twin pregnancies
TLDR
To analyze the value of Down syndrome second‐trimester maternal serum screening in large series of twin pregnancies, a large number of twin pregnant women are surveyed.
Multi‐centre first‐trimester screening for Down syndrome in the Netherlands in routine clinical practice
This is the first report on the results of a first‐trimester combined‐test screening programme in the Netherlands in a multi‐centre routine clinical setting.
Population screening for fetal trisomy 21: easy access to screening should be balanced against a uniform ultrasound protocol
To evaluate the performance of a first‐trimester fetal aneuploidy screening program, with a documented underestimation of nuchal translucency thickness measurements (NT) compared to the Fetal
First trimester Down syndrome screening with dried blood spots using a dual analyte free beta hCG and PAPP‐A immunofluorometric assay
To determine the effectiveness of first trimester Down syndrome screening with dried blood spots using a dual analyte free beta human chorionic gonadotrophin (hCG)/pregnancy‐associated plasma protein
Second‐trimester prenatal screening for trisomy 21 using biochemical markers: a 7‐year experience in one cytogenetic laboratory
Screening for trisomy 21 in the second trimester of pregnancy using biochemical markers is an established part of prenatal care in many developed countries.
Aneuploidy screening in the first trimester
  • K. Spencer
  • Medicine
    American journal of medical genetics. Part C, Seminars in medical genetics
  • 2007
This article reviews the performance of first trimester screening for chromosomal anomalies using various combinations of ultrasound and maternal serum biochemical modalities. Detection rates in
Expectation and knowledge of women undergoing first‐trimester combined screening for Down syndrome in a Chinese population
TLDR
To study the preference of pregnant women regarding the time taken to report the results of first‐trimester combined screening for Down syndrome and their knowledge about it, a study of women's knowledge of the procedure and their preference is studied.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 17 REFERENCES
Combined ultrasound and biochemical screening for Down's Syndrome in the first trimester: a Scottish multicentre study
TLDR
The use of ultrasound measurements of fetal nuchal translucency obtained in a routine antenatal clinic setting in combination with appropriate biochemical markers as a first trimester screening test for Down's Syndrome is evaluated.
Second trimester trisomy 21 maternal serum marker screening. Results of a countrywide study of 854 902 patients
TLDR
A study of the countrywide trisomy 21 screening based on second trimester maternal serum markers in France finds that maternal serum marker screening is governed by specific legislation.
First‐Trimester Down Syndrome Screening Using Dried Blood Biochemistry and Nuchal Translucency
TLDR
First-trimester screening for Down syndrome and trisomy 18 is effective and offers substantial benefits to clinicians and patients.
The first trimester ‘combined test’ for the detection of Down syndrome pregnancies in 4939 unselected pregnancies
TLDR
The high detection rate (DR) for Down syndrome (DS) pregnancies which can be achieved by measuring fetal nuchal translucency early in pregnancy can be improved by combining it with placental hormones and maternal age and the ‘combined test’ was assessed.
Evaluation of first trimester maternal serum and ultrasound screening for Down's syndrome in Eastern and Northern Finland
TLDR
In Eastern and Northern Finland, during the year 1999, first-trimester ultrasonographic and serum screening for trisomy 21 was offered, with measurements of maternal serum PAPP-A and β-hCG, yielding the detection of eight foetuses with Down's syndrome.
Appropriate biochemical parameters in first‐trimester screening for Down syndrome
TLDR
Meta‐analysis was used to calculate maternal serum marker distribution parameters for Down syndrome risk estimation in the first trimester and it is estimated that screening at 9–11 weeks with PAPP‐A and free β‐hCG will yield a 64.6 per cent detection rate for a 5 per cent false‐positive rate.
One‐stop clinic for assessment of risk for trisomy 21 at 11–14 weeks: a prospective study of 15 030 pregnancies
To evaluate the performance of a one‐stop clinic for assessment of risk (OSCAR) for trisomy 21 by a combination of maternal age, fetal nuchal translucency (NT) thickness and maternal serum free
One stop clinic for assessment of risk for fetal anomalies: a report of the first year of prospective screening for chromosomal anomalies in the first trimester
Objective To evaluate the introduction of a one stop multidisciplinary clinic for screening for fetal chromosomal abnormalities in the first trimester by a combination of maternal serum biochemistry
Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening.
TLDR
It is demonstrated that Down's syndrome screening using the combined test in the first trimester had a higher detection rate than that of serum screening in the second trimester.
Integrating antenatal Down's syndrome screening
  • H. Cuckle
  • Medicine
    Current opinion in obstetrics & gynecology
  • 2001
TLDR
The concurrent use of first trimester serum markers and ultrasound nuchal translucency is the most practical and the combination of three modalities with non-disclosure of the intermediate results is more efficient, but the gain in detection is too small to warrant the wait for up to 4 weeks for results.
...
1
2
...